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propofol in critically ill patients, and subsequently determining the best strategy 
for administering propofol. Methods: Costs of propofol-related infection and the 
different strategies of administration of propofol were computed according to the 
literature and microcosting method. The additional length of stay in ICU due to 
major infections related to propofol administration was estimated using the disabil-
ity model, assuming a cost of CHF 2’118/intensive care unit day (local cost). The cost 
of each strategy was estimated based on all costs and on the probability of major 
infections related to propofol administration. Results: According to the links 
found in the literature by genotyping bacteria (syringe-patient), we assumed that a 
patient has a mean 22.6% risk of developing an infection by a contaminated prepa-
ration of propofol. Thus, the ready-to-use syringe and syringes drawn from vials 
have an infection probability of 0.0014 [0.0009 – 0.0038] and 0.0118 [0.0056 – 0.0181] 
respectively. Probability of infection and the extended length of stay were the cost-
drivers of this analysis. Ready-to-use syringes of propofol saved money, decreasing 
the cost by at least CHF 251 per sedation. Ready-to-use syringes remained a cost 
saving strategy when the propofol related infection rate probability according to the 
literature was as high as 0.38%. ConClusions: Ready-to-use syringes of propofol 
save money by preventing major infections related to its administration.
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objeCtives: Averting 20% of new HIV infections, the country has to achieve 80% 
national circumcision coverage. Given the inadequacy of human resource at cir-
cumcision centers in Uganda, we conducted a study to assess the cost-effectiveness 
of PrePex device (none surgical) and Dorsal-slit technique (surgical) for scaling-up 
adult safe medical male circumcision. Methods: In a four weeks cost effective-
ness course project during November 2012, we modeled the costs and effects of 
male circumcision of the 2 commonest strategies (Dorsal-slit technique as standard 
and PrePex device) used in Uganda. Effectiveness was defined as days of complete 
healing measured by costs from start of procedure to complete healing. This was 
the time until end of each procedure when all scores for drainage from incision, 
epithelialization, granulation of tissue, and edema were zero. We estimated costs 
and effects from previous studies in developing countries. Direct and indirect costs 
were included in a cost effectiveness analysis with limited government perspective. 
Costs for demand creation (training, patient counseling, and promotion campaigns) 
were excluded. One-way sensitivity analysis was done by varying costs and days of 
complete healing as main model parameters. Analyses were done using TreeAge 
Pro-2011 software. Results: PrePex (none surgical) utilized $52.13 over the days 
to complete healing (31 days) compared to dorsal-slit (surgical) utilizing $67.8 over 
the days to complete healing (23 days). PrePex was less costly ($52) and with lowest 
adverse-events (0.98) compared to dorsal-slit technique 0.96 adverse-events cost-
ing $65.9. PrePex device was mostly not sensitive to changes in costs and days to 
complete healing. ConClusions: PrePex device was cost-saving and cost effective.
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objeCtives: Two major clinical trials examined the efficacy of caspofungin (CAS) 
and voriconazole (VORI) for empiric therapy of febrile neutropaenia (FN). We inves-
tigated the cost-effectiveness of empiric CAS vs. VORI in FN from the Turkish per-
spective. Methods: The downstream consequences of CAS or VORI were captured 
through decision tree analysis. Outcome measures included success, breakthrough 
fungal infection, persistent base-line fungal infection, persistent fever, premature 
discontinuation and death. Probability data were extracted from the major stud-
ies. An expert panel estimated health care resource consumption and alternative 
treatment after initial failure with either agent. Cost was based on 2012 data using 
Turkish Lira (TL). Deterministic and probabilistic sensitivity analyses were per-
formed. Results: Compared to VORI, CAS was dominant by TL2,533, TL29,256 and 
TL2,536 per patient treated, successfully treated and patient survival, respectively 
(approx. USD1,414, 16,328 and 1,415). CAS had a higher likelihood of success and 
lower mortality than VOR (34.17% vs. 26.02% and 7.37% vs. 7.95%, respectively). 
Increasing the list cost or length of stay (LOS) for CAS by > 35% or 1.3 days, respec-
tively, changes the study outcomes. A decrease of list cost or LOS for VOR by > 32% 
or 1.2 days resulted in it being favorable. Removing fever resolution as part of the 
composite outcome afforded a contracted difference (CAS preferred by TL298 and 
299 per patient treated and surviving with VORI preferred by TL488 per patient 
successfully treated). Monte Carlo simulation of 10,000 subjects, with variability 
imputed on the outcome probabilities taken from the literature, LOS and hospitali-
sation costs, resulted in a 78.8% chance of favoring CAS. ConClusions: There is 
a high likelihood of CAS being cost-effective compared to VORI in the treatment of 
FN in Turkey. Sensitivity analyses highlighted a robust advantage towards CAS. The 
model is moderately sensitive to changes in LOS or cost of each agent.
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using the constant discounting approach. The empirical , hyperbolic and propor-
tional discounting methods provided ICERs three times higher. The time-shifted and 
stepwise discounting led to favorable ICERs that were much below the NICE thresh-
old. ConClusions: The use of different discounting approaches had a considerable 
effect on the cost-effectiveness results. For preventive programs and vaccines con-
stant discounting approach was unfavorable since the health benefits are revealed 
decades later. Constant discounting could not justify the theory of social and indi-
vidual time preference. The empirical discounting though discounted the outcomes 
at a much slower rate in the long term; the approach remained unfavorable owing to 
the heavy discounting in the short term. The time-shifted and stepwise discounting 
were feasible for the vaccines as they related to the moment of risk reduction and 
were persistent with the time-preference theory, respectively.
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objeCtives: A pivotal clinical trial failed to demonstrate non-inferiority of voricona-
zole (VORI) vs. liposomal amphotericin B (LAMB) for empiric treatment of febrile neu-
tropaenia (FN). This study investigated the cost-effectiveness of the two options from 
the Turkish health care system’s perspective. Methods: A decision-tree analysis 
was used to capture downstream consequences of each agent. Outcome measures 
included success, breakthrough fungal infection, persistent base-line fungal infection, 
persistent fever, premature discontinuation and death. Probability data were extracted 
from the published clinical trial. Resource consumption and alternative treatment 
after initial failure with either agent were estimated by an expert panel. Cost was 
based on 2012 data within Turkey. Deterministic and probabilistic sensitivity analyses 
were performed to determine the model’s robustness. Results: Compared to LAMB, 
VORI was the cost-effective alternative per patient treated and per patient survival 
(by TL2,523 (approx USD1,396) and TL2,520 (approx USD1,394), respectively). LAMB 
was preferred when considering the cost per successfully treated patient (TL5,362 
difference in favor of LAMB, approx USD2,966). LAMB had a higher likelihood of suc-
cess (30.57% vs. 26.02%) and lower probability of death than VORI (5.92% vs. 7.95%). 
Increasing the list cost or length of stay (LOS) of VORI by > 32.4% or 1.2 days, respec-
tively, changes the study outcomes. Decreasing list cost or LOS for LAMB by > 15.8% 
or 1.0 days, respectively, resulted in LAMB becoming favorable. Monte Carlo simula-
tion (MCS) of 10,000 subjects, with variability imputed upon the published outcome 
probabilities, LOS and hospitalization costs, resulted in a 69.4% chance of favoring 
VORI. ConClusions: VORI appears to be cost-effective when compared to LAMB in 
the empiric treatment of FN from the Turkish perspective. One-way sensitivity analy-
ses did not change the conclusion with MCS indicating a 69.4% chance of favoring 
VORI. The outcome was highly sensitive to list cost and LOS.
PIN87
NoN-hoMogENEous Cost-EffECtIvENEss MoDElINg of a NEw Chg-
DrEssINg for PrEvENtINg CathEtEr-rElatED blooDstrEaM INfECtIoNs 
for PatIENts IN INtENsIvE CarE uNIts
Maunoury F.1, Motrunich A.1, Ruckly S.2, Timsit J.F.2
1Statésia, Le Mans, France, 2Grenoble University Hospital, Grenoble, France
objeCtives: Catheter-related bloodstream infection (CRBSI) is a frequent (1-5/1000 
catheter-days) and life-threatening complication in intensive care unit (ICU), pre-
ventable by systematic use of a new antimicrobial transparent dressing containing 
a chlorhexidine gluconate (CHG) hydrogel (60% risk reduction in a recent RCT). Our 
purpose is to evaluate the advantages of routine use of the new CHG-dressing to 
secure central lines of patients in ICU from the medico-economic viewpoint compared 
to non-antimicrobial (reference). Both medical and economic criteria are embedded 
into an analytic decision model to support the choice of the best dressing strat-
egy. Methods: A 30-day ICU-time non-homogeneous markovian model comprises 
eight states: five combining either occurrence or no-occurrence of: CRBSI, contact 
dermatitis, and the need of a new central line; one for changing alternative dressing 
in case of dermatitis and two absorbent states (death and discharge). The probabili-
ties of events derive a multicentre RCT on 1,879 patients. Monte Carlo simulations 
of 1,000 patients are used for probabilistic sensitivity analysis and 95% confidence 
intervals (CI) calculations. The final health outcome is the number of CRBSI averted. 
Costs of ICU stay are updated from estimations of a French study from 2010. This 
economic evaluation takes into account ICU perspective in France. Results: The 
CHG-dressing prevents 11.75 infections (95% CI: [-19.64; -3.85], number needed to 
treat= 85) for 1,000 patients as estimated via probabilistic cost-effectiveness sensitivity 
analysis. The mean adjusted cost per patient is € 2013 21,391 [95% CI: € 20,339; € 22,443] 
for the CHG-dressing group and € 2013 20,882 [95% CI: € 19,905; € 21,859] for the reference 
dressing. ConClusions: The CHG-dressing, significantly more efficacious to prevent 
CRBSI when compared to the reference dressing, contributes to preserve patients’ 
health capital at the same cost for the ICU. According to the base case scenario the 
CHG-dressing is more cost-effective than the reference dressing.
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objeCtives: Primary nosocomial bloodstream infections (BSI) (5-15% of all infec-
tions) are associated with increased length of stay and additional hospital costs. 
Propofol infusions, commonly used for sedation in intensive care units (ICU), are 
formulated in lipid emulsion which promotes microbial growth. The present study 
aimed at identifying the probabilities and costs of contamination of syringes of 
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objeCtives: To assess the cost-effectiveness of quadrivalent influenza vaccine 
(QIV) compared to trivalent vaccine (TIV) in the Italian population aged 65 years or 
more or at high-risk for influenza. Methods: A static and multi-cohort Markov 
model was modified to simulate the disease process of influenza (type A and B) over 
a lifetime horizon using annual cycles. Several cohorts based on the Italian popu-
lation (nine different age-groups and two level of risks: high and low) entered the 
model and could be vaccinated with QIV or TIV. Vaccine coverage rate, epidemiologi-
cal and demographic estimates were taken from local statistics, surveillance data 
and Italian published studies, while circulation of type A versus B virus and type of 
lineage was taken from Euroflu estimates (from 2003-2004 to 2012-2013). Vaccine 
efficacy against influenza A and B were taken from 2 meta-analyses of clinical trials. 
Costs and resource use were based on local tariffs and published estimates (price 
year 2013). Quality of life scores were obtained from a Spanish study, using the EQ-5D 
questionnaire. The perspective of the National Health Service (NHS) was used and a 
3% discount rate was applied to costs and benefits, according to Italian guidelines. 
To deal with the issue of uncertainty both deterministic and probabilistic sensitivity 
analyses were conducted. Results: In the basecase, the incremental cost per QALY 
and per LY saved for QIV versus TIV were € 10,940 and € 9,452, respectively. The most 
sensitive parameters were vaccine efficacy and probability of circulation of virus 
A versus B, but the probabilistic analysis showed that at a threshold of € 50,000 per 
QALY, there was about 90% probability for QIV to be cost-effective. ConClusions: 
This study suggests that the introduction of QIV at the same level of price of the 
most recent adjuvated vaccines is likely to be a cost-effective strategy from the 
perspective of the Italian NHS.
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objeCtives: Chickenpox, or varicella, is a highly communicative infectious dis-
ease affecting mainly young children. Varicella is self-limiting in the majority 
of cases, yet serious complications, including secondary bacterial infections of 
skin and soft tissues, pneumonia and encephalitis, can occur and result in hos-
pitalization. Varicella vaccine is an effective post-exposure prophylaxis (PEP) of 
chickenpox. This study aimed to analyze cost-effectiveness of PEP using varicella 
vaccine for pediatric patients from the perspective of public health care provider in 
Hong Kong. Methods: A decision tree was designed to compare cost and clinical 
outcomes of PEP with varicella vaccine versus no PEP in pediatric patients (aged 
1-18 years old) susceptible to chickenpox with household exposure. Two tiers of 
outcomes were simulated: 1) Total direct medical cost, and 2) the quality-adjusted 
life year (QALY) loss associated with chickenpox. Model inputs were retrieved from 
local epidemiology and medical literature. Sensitivity analysis was performed on 
all parameters to test the robustness of model results. Results: Base-case analy-
sis showed PEP with varicella vaccine to be less costly (expected cost USD320 vs. 
USD731) with lower QALY loss (0.00423 QALYs vs. 0.01122 QALYs), comparing to no 
PEP. Sensitivity analysis showed that PEP with varicella vaccine was less costly if 
PEP effectiveness was > 6.2% or chickenpox infection rate without PEP was > 8.6%. 
In 10,000 Monte Carlo simulations, PEP with vaccine was cost-effective in over 
99% of the time with mean cost saving of USD611per patient (95% CI USD602-620; 
P< 0.001) and lower mean QALY loss of 0.00809 QALYs (95% CI 0.00802-0.00816 
QALYs; P< 0.001). ConClusions: Using varicella vaccine as PEP seems to be a 
cost-saving strategy to avert QALY loss in susceptible pediatric patients exposed 
to chickenpox in Hong Kong.
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objeCtives: Sofosbuvir is a uridine analogue polymerase inhibitor. Pan-genotypic 
efficacy and safety have been demonstrated in four phase III clinical trials of SOF 
administered with ribavirin (RBV) or with a combination of pegylated interferon alfa 
and RBV (PR). This analysis evaluated the long-term outcomes of SOF/RBV in treat-
ment-naïve (TN) genotype (GT) 1/4/5/6 and TN, treatment-experienced (TE), interferon 
ineligible (TNI) GT 2 and 3 patients Methods: A Markov-model followed a cohort 
of 10,000 patients for a lifetime, with 50% initiating treatment at the compensated 
cirrhotic stage. In GT 1, 4/5/6 TN patients, SOF/PR for 12 weeks was compared to, 
telaprevir (TVR) or PR, respectively. SOF/RBV for 12 or 16 weeks for GT 2 and 3, respec-
tively, was compared to no treatment for TNI and TE, and PR for 24 or 48 weeks (PR24/
PR48) for TN and TE respectively. SVR 12 weeks have been reported as 90% for TN GT 
1 and 97% for GT 4/5/6 patients; 78% for patients with no treatment option (TNI and 
TE); 97% and 56% for GT 2 and 3 TN; for GT 2 and 3 TE, 86% and 30% with 12-week 
and, 94% and 62% with 16-week regimens, respectively. Results: SOF was shown 
to be highly effective in preventing advanced liver disease (ALD) and mortality due 
to HCV across all GTs. This was particularly favorable for patients with no current 
treatment option (TNI and TE) where up to 7,000 ALD cases can be avoided and more 
than 200 lives saved. The model demonstrated that in GT 1 and 4/5/6 TN patients, 
SOF/PR prevented around 5,000 and 900 more ALD cases than PR and TVR treatment 
arms, respectively. ConClusions: SOF, including within interferon-free regimens, 
was shown to be highly effective in preventing progression to ALD and reducing HCV-
related mortality, particularly in patients with no current treatment option.
objeCtives: To conduct pharmacoeconomic analysis of ritonavir-boosted ataza-
navir (ATV/r) vs ritonavir-boosted lopinavir (LPV/r) and ritonavir-boosted darunavir 
(DRV/r) in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in 
treatment-naïve adult patients with HIV-infection from Russian health care sys-
tem point of view. Methods: Cost-effectiveness analysis (CEA) with calculation of 
incremental cost-effectiveness ratio (ICER) was used for comparison of ATV/r with 
LPV/r. Cost-minimization analysis (CMA) with calculation of cost minimization dif-
ference (CMD) was used for comparison of ATV/r with DRV/r. Direct comparison of 
clinical efficacy and safety of ATV/r vs LPV/r was based on the results of randomized 
controlled trial (RCT) CASTLE. Indirect comparison of clinical efficacy and safety 
of ATV/r with DRV/r was performed on the basis of results of RCTs CASTLE and 
ARTEMIS. Virological response after 96 weeks of treatment and protease inhibitors 
(PIs)-induced diarrhea were considered as clinical efficacy and safety outcomes, 
respectively. Direct medical costs were calculated for the hypothetical cohort of 100 
patients treated for 96 weeks. Results: ATV/r + NRTIs had statistically significant 
higher rate of virological response after 96 weeks of treatment than LPV/r + NRTIs 
(risk ratio (RR) = 1.090 [95% CI 1.002; 1.186], p< 0.05) with statistically significant 
lower risk of PI-induced diarrhea (RR = 0.202 [95% CI 0.107; 0.381], p< 0.0001). There 
were no statistically significant difference between combinations ATV/r + NRTIs 
and DRV/r + NRTIs in terms of rate of virological response and risk of PI-induced 
diarrhea (RR = 0.981 [95% CI 0.869; 1.107], p= 0.77 and 0.543 [95% CI 0.227; 1.296], 
p= 0.17, respectively). ICER for ATV/r vs LPV/r was 4063.58 EUR per one additional 
patient with virological response. CMD for ATV/r vs DRV/r was 5485.38 EUR per 
patient. ConClusions: ATV/r is more preferable than LPV/r and DRV/r for admin-
istration in combination with NRTIs in treatment-naïve adult patients with HIV 
infection.
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objeCtives: Herpes Zoster (HZ) is a painful skin rash that occurs most frequently 
among the elderly. A vaccine has recently been licensed in Europe to prevent HZ 
in individuals aged ≥ 50 years. As of today, the actual annual waning-rate (WR) 
of vaccine-induced-immunity (VI) is unknown. To investigate the impact of dif-
ferent WRs on the incremental-cost-effectiveness-ratio (ICER) at different ages at 
vaccination, we performed a health economic analysis for the German statutory-
health-insurance setting. Methods: Based on a Markov-model, we compared a 
HZ-vaccination-strategy to a scenario without vaccination in Germany targeting 
different cohorts to identify the most efficient age at vaccination (50, 60, or 70 
years). A societal-perspective (SP) was considered, country- and age-specific demo-
graphic, epidemiological, and cost-of-illness input-data were utilized. We assumed 
a vaccine-price of 140.48 Euro/dose and 10 year stable VI. Thereafter an exponential 
waning of VI based on several annual relative WR (0, 2.5, 5, 7.5, 10 and 50%) was 
assumed. All monetary amounts were in Euro 2010. The cycle-length was a quarter; 
we considered a lifelong time-horizon. The discount-rate was 3% for outcomes 
and costs. Results were presented as costs/quality-adjusted life-year (QALY) gained 
ICERs. Results: With annual WR < 5% ICERs increase with age at vaccination from 
50 (0% WR: 16,567€ /QALY gained) to 70 years (0% WR: 37,285€ /QALY gained). When 
WR is ≥ 5% the vaccination-age-specific ICERs become U-shaped with the minimum 
ICERs at 60 years (5% WR: 25,474€ /QALY gained). With high annual WR (50%) the 
ICERs at vaccination-age 70 (50,847€ /QALY) are lower than ICERs at 50 years (56,871€ /
QALY). ConClusions: The annual WR has a high impact on vaccination-age-spe-
cific ICERs. To obtain lowest ICERs, HZ-vaccine should be given early in life (e.g. 50 
years) if WR is low. When annual WR is > 4%, the most efficient age at vaccination is 
60 years. Evidence on the actual WR after HZ-vaccination has yet to be established.
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objeCtives: The Netherlands has no varicella vaccination in its National 
Immunization Program (NIP). Although varicella is regarded as a mild disease, imple-
mentation of varicella vaccination in the immunization schedule of several countries 
has shown to be cost-effective. Dutch children are infected with varicella zoster virus 
at younger age and make less use of the health care system as compared to other 
European countries. Therefore, a specific cost-effectiveness study of varicella vac-
cination for The Netherlands is needed. We aimed to estimate the incremental cost-
effectiveness ratio (ICER) of universal vaccination of children against varicella in the 
Dutch NIP as compared with no such vaccination. Methods: A static cohort model 
was developed to assess the cost-effectiveness of varicella childhood vaccination 
in the first 30 years. Several vaccination strategies were explored by varying the age 
of the booster vaccination. Dutch sources of varicella incidence and health care use 
were combined with vaccine efficacy data from other countries. This study was per-
formed from the societal perspective as well as from the payer’s perspective. Results 
were expressed in euros (€ ) per quality-adjusted life year (QALY) gained. Results: 
Vaccinating a birth-cohort of 180,000 children could avert 105,091 varicella cases and 
save 301.1 QALYs and € 13.7 million of direct and indirect costs. The optimal vacci-
nating-strategy from cost-effectiveness point of view was vaccinating at 14 months 
and 4 years. This scenario resulted in an ICER of € 2844/QALY gained from the societal 
perspective and € 40,582/QALY gained from the health care payer’s perspective, when 
a vaccine price of € 45 was used. Results were sensitive to vaccine price, waning rate of 
the second vaccination and indirect costs. ConClusions: Introduction of varicella 
vaccination in the Dutch NIP would be cost-effective from the societal perspective 
when a threshold of € 20.000/QALY gained was used, which corresponds to the mini-
mum threshold mentioned for the Dutch context.
